Brought to you by 
Cara licenses Enteris' Peptelligence to develop oral formulation of Korsuva
11 Oct 2022
Executive Summary
Enteris BioPharma Inc. granted Cara Therapeutics Inc. a non-exclusive worldwide license (excluding Japan and South Korea) to its Peptelligence drug delivery technology to use in the development, manufacture, and commercialization of Cara's oral Korsuva (difelikefalin; CR845), a long-acting synthetic peptide peripheral kappa opioid receptor (KOR) agonist.
Deal Industry
- Pharmaceuticals
-
Pharmaceuticals
-
Drug Delivery
- Macromolecule
-
Drug Delivery
-
Biotechnology
- Large Molecule
Deal Status
- Final
Deal Type
-
Alliance
- Includes Equity
- Includes Royalty or Profit Split Information
- Intra-Biotech Deal
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Cara licenses Enteris' Peptelligence to develop oral formulation of Korsuva
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice